157 related articles for article (PubMed ID: 10976637)
1. Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?
van Boxel-Dezaire AH; van Trigt-Hoff SC; Killestein J; Schrijver HM; van Houwelingen JC; Polman CH; Nagelkerken L
Ann Neurol; 2000 Sep; 48(3):313-22. PubMed ID: 10976637
[TBL] [Abstract][Full Text] [Related]
2. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis.
Khademi M; Wallström E; Andersson M; Piehl F; Di Marco R; Olsson T
J Neuroimmunol; 2000 Mar; 103(2):202-10. PubMed ID: 10696916
[TBL] [Abstract][Full Text] [Related]
3. Interferon beta-1b treatment modulates TNFalpha and IFNgamma spontaneous gene expression in MS.
Gayo A; Mozo L; Suárez A; Tuñón A; Lahoz C; Gutiérrez C
Neurology; 1999 Jun; 52(9):1764-70. PubMed ID: 10371521
[TBL] [Abstract][Full Text] [Related]
4. Interferon beta-1b treatment in patients with relapsing--remitting multiple sclerosis under a standardized protocol in Spain.
Arbizu T; Alvarez-Cermeño JC; Decap G; Fernández O; Uría DF; García Merino A; Izquierdo G; Montalbán X
Acta Neurol Scand; 2000 Oct; 102(4):209-17. PubMed ID: 11071104
[TBL] [Abstract][Full Text] [Related]
5. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
[TBL] [Abstract][Full Text] [Related]
6. Effects of interferon β-1a and interferon β-1b monotherapies on selected serum cytokines and nitrite levels in patients with relapsing-remitting multiple sclerosis: a 3-year longitudinal study.
Stępień A; Chalimoniuk M; Lubina-Dąbrowska N; Chrapusta SJ; Galbo H; Langfort J
Neuroimmunomodulation; 2013; 20(4):213-22. PubMed ID: 23711618
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 17F level and interferon β response in patients with multiple sclerosis.
Hartung HP; Steinman L; Goodin DS; Comi G; Cook S; Filippi M; O'Connor P; Jeffery DR; Kappos L; Axtell R; Knappertz V; Bogumil T; Schwenke S; Croze E; Sandbrink R; Pohl C
JAMA Neurol; 2013 Aug; 70(8):1017-21. PubMed ID: 23732754
[TBL] [Abstract][Full Text] [Related]
8. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders.
Carrieri PB; Ladogana P; Di Spigna G; de Leva MF; Petracca M; Montella S; Buonavolontà L; Florio C; Postiglione L
Immunopharmacol Immunotoxicol; 2008; 30(4):1-9. PubMed ID: 18686100
[TBL] [Abstract][Full Text] [Related]
10. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b.
Iarlori C; Reale M; Lugaresi A; De Luca G; Bonanni L; Di Iorio A; Feliciani C; Conti P; Gambi D
J Neuroimmunol; 2000 Jul; 107(1):100-7. PubMed ID: 10808056
[TBL] [Abstract][Full Text] [Related]
11. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
[TBL] [Abstract][Full Text] [Related]
12. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
13. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy.
Trojano M; Liguori M; Paolicelli D; Zimatore GB; De Robertis F; Avolio C; Giuliani F; Fuiani A; Livrea P;
Mult Scler; 2003 Oct; 9(5):451-7. PubMed ID: 14582768
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
[TBL] [Abstract][Full Text] [Related]
15. Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis.
Trenova AG; Manova MG; Kostadinova II; Murdjeva MA; Hristova DR; Vasileva TV; Zahariev ZI
Folia Med (Plovdiv); 2011; 53(2):29-35. PubMed ID: 21797104
[TBL] [Abstract][Full Text] [Related]
16. In vivo effect of interferon-beta 1a on interleukin-12 and TGF-beta(1) cytokines in patients with relapsing-remitting multiple sclerosis.
Losy J; Michałowska-Wender G
Acta Neurol Scand; 2002 Jul; 106(1):44-6. PubMed ID: 12067328
[TBL] [Abstract][Full Text] [Related]
17. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS.
Kracke A; von Wussow P; Al-Masri AN; Dalley G; Windhagen A; Heidenreich F
Neurology; 2000 Jan; 54(1):193-9. PubMed ID: 10636147
[TBL] [Abstract][Full Text] [Related]
18. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
[TBL] [Abstract][Full Text] [Related]
19. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
20. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Koch-Henriksen N; Sørensen PS; Christensen T; Frederiksen J; Ravnborg M; Jensen K; Heltberg A; Kristensen O; Stenager E; Petersen T; Hansen T;
Neurology; 2006 Apr; 66(7):1056-60. PubMed ID: 16510769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]